Pathos AI Secures $237 Million Series E Funding Led by Bristol Myers Squibb
Pathos AI has successfully raised $237 million in a Series E funding round, with Bristol Myers Squibb leading the investment. This event was reported by Axios, STAT, WHBL News, and marketscreener.com, confirming the significant capital injection into the AI drug firm. STAT additionally reported that this funding round pushes Pathos AI's valuation to $3 billion, while WHBL News highlighted a partnership with Tempus AI aimed at advancing drug development.
4 articles from 4 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
4 outlets covered “Pathos AI Secures $237 Million Series E Funding Led by Bristol Myers Squibb”. All of them report the following:
- Pathos AI received funding
- Bristol Myers Squibb is involved in the funding
- The funding amount is $237 million
Which figures do outlets report differently?
1 figure in this story is reported with conflicting values:
Which outlets covered this?
All 4 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.